Biological targets of antitumor indolocarbazoles bearing a sugar moiety.
Natural and synthetic indolocarbazole compounds have triggered considerable interest since the discovery in 1986 of the inhibitory properties of staurosporine toward protein kinase C (PKC). Later, it has been shown that indolocarbazole compounds may inhibit various kinases, such as cyclin dependent-kinases and/or topoisomerase I, someones behave only as DNA intercalators. In this review are presented various indolocarbazole compounds bearing a sugar moiety and their biological targets. The relevance of these targets to develop indolocarbazole compounds as potential antitumor agents is discussed.
Prudhomme
Michelle
M
Laboratoire SEESIB, UMR 6504 CNRS, Université Blaise Pascal, 24, Avenue des Landais, 63177 Aubiere, France. mprud@chimie.univ-bpclermont.fr
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry*; D002227:Carbazoles / Q000008:administration & dosage / Q000737:chemistry*; D002241:Carbohydrates / Q000008:administration & dosage / Q000737:chemistry*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000737:chemistry*; D019311:Staurosporine / Q000008:administration & dosage / Q000737:chemistry
D000970:Antineoplastic Agents; D002227:Carbazoles; D002241:Carbohydrates; D007211:Indoles; C075954:indolo(3,2-b)carbazole; D019311:Staurosporine